Q4 FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 25, 2026
Kiora Pharmaceuticals, Inc. (KPRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$1.9 million. As of Jun 30, 2026 it held $16.8 million in cash and investments and $333,022 in total debt.
Revenue
$0
Net income
$-2.08M
+3.4% vs year-ago quarter
Operating cash flow
$-1.89M
+50.3% vs year-ago quarter
Free cash flow
$-1.92M
+50.1% vs year-ago quarter
EPS
$-0.34
+37.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
4.42M
+28.9% vs year-ago quarter
Net cash
$16.51M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KPRX (Nasdaq), KPHMW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Encinitas, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1372514
- Former names
- EYEGATE PHARMACEUTICALS INC (until Nov 4, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 |
| Operating income | -$2.2M | -$2.5M | -$7.3M | -$794,437 | -$2.4M |
| Net income | -$2.1M | -$2.4M | -$6.5M | $26,806 | -$2.2M |
| Diluted EPS | -$0.34 | -$0.58 | -$1.66 | $0.01 | -$0.54 |
| Operating cash flow | -$1.9M | -$3.2M | -$2.2M | -$1.3M | -$3.8M |
| Free cash flow | -$1.9M | -$3.2M | -$2.3M | -$1.3M | -$3.8M |
| Total assets | $23.8M | $21.2M | $24.3M | $29.9M | $31.9M |
| Total liabilities | $6.9M | $7.3M | $8.1M | $7.5M | $9.8M |
| Stockholders' equity | $16.9M | $13.9M | $16.1M | $22.4M | $22.1M |
| Cash and investments | $16.8M | $13.9M | $17.1M | $19.4M | $20.7M |
| Total debt | $333,022 | $373,586 | $368,259 | $404,165 | $430,405 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 29, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Aug 19, 2026 | Aug 19, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2026 | Aug 7, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 18, 2026 | Jun 18, 2026 |
All 926 Kiora Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.